---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-245704"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:47:47.463341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M

## Summary
- Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
- Mean annualized eGFR slope of -0.6 mL/min/1.73m2/year; 90% treatment completion rate.
- Phase 3 ORIGIN 3 topline expected Q2 2025; BLA submission planned H2 2025; commercial launch target 2026.
- Preliminary unaudited cash, cash equivalents and marketable securities ~$353.2M as of Sep 30, 2024.
- Data simultaneously published in Journal of the American Society of Nephrology; presented at ASN Kidney Week.

## SEC filing metadata
- accession: 0001193125-24-245704
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312524245704/0001193125-24-245704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312524245704/d891191d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-245704
- JSON: https://secwatch.observer/filing/0001193125-24-245704.json
- Plain text: https://secwatch.observer/filing/0001193125-24-245704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.